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Serving as the cellular factory for the biogenesis of 
ribosomes (the molecular machines responsible for the 
decoding of mRNAs to proteins), the nucleolus controls a 
vast array of physiological processes including cell growth 
and proliferation. It thus comes as no surprise that inherited 
and acquired abnormalities in ribosome biogenesis can lead 
to tumorigenesis and that changes in size and number of the 
nucleoli, which are assumed to reflect the rate of ribosome 
production, have long been recognized as feature of a large 
number of tumor types. To safeguard against the potentially 
tumorigenic effects of deregulated ribosome biogenesis, 
cells activate the p53 tumor suppressor by re-directing the 
ribosomal protein (RP) L5/RPL11/5S rRNA pre-ribosomal 
complex from ribosome biogenesis to HDM2 binding, 
alleviating its inhibitory effect over p53 [1].
However, it has long been appreciated that upon 
exposure of cells to distinct genotoxic agents that also 
perturb nucleolar structure and ribosome biogenesis, the 
nucleolar proteins nucleophosmin (NPM) and alternative 
reading frame (ARF) tumor suppressor are engaged to 
activate p53. Thus, oncogene-induced replication stress and 
genotoxic insults ensue DNA damage responses that impair 
the nucleolar interaction of ARF with NPM, leading to the 
release of ARF to the nucleoplasm where it binds HDM2 and 
inhibits HDM2-mediated degradation of p53 [2]. NPM is 
also mobilized to the nucleoplasm, although with somewhat 
slower kinetics, to associate with free, p53-bound or de novo 
synthesized HDM2 [2]. The ensuing accumulation of p53 
is required for cell cycle arrest, senescence or apoptosis of 
damaged cells. The central role of NPM in these nucleolus-
orchestrated responses is further highlighted by the fact 
that NPM mutations which render it cytoplasmic are 
associated with genomic instability and the development of 
hematopoietic malignancies such as acute myeloid leukemia 
(AML) [2].
A recent study by Kanellis et al. [3] provides novel 
insight into the intricate management of p53 activation upon 
“nucleolar stress” by identifying Tumor Progression Locus 
2 (TPL2; also known as COT and MAP3K8) as a physical 
and functional partner of NPM. TPL2 has mostly been 
appreciated as a cytoplasmic kinase involved in the wiring 
of pro-inflammatory signal transduction [4]. Kanellis et al. 
have found that in malignant cells and normal fibroblasts a 
fraction of TPL2 resides in the nucleolus where it associates 
with and phosphorylates a pool of NPM molecules at 
Thr199. As this phosphorylation event is required for NPM 
ubiquitination and proteasomal degradation, TPL2 appears 
to participate in the maintenance of physiological levels 
of NPM. Upon genotoxic stress this NPM pool becomes 
de-phosphorylated by activated PP1β [5], stabilizes and 
translocates to the nucleoplasm where it sequesters HDM2 
away from p53 leading to a robust p53 response (Figure 1). 
Consistent with this novel TPL2 function in p53 activation, 
several human cancers display reduced expression of TPL2 
[4, 6] and recently published genetic evidence in the mouse 
suggests that this kinase operates in epithelial cells as 
suppressor of malignant transformation [6, 7].
How do these observations fit in the aforementioned 
NPM-centered model? The work by Kanellis et al. 
suggests that when TPL2 levels are reduced, the fraction 
of NPM that becomes phosphorylated diminishes. This 
in turn results in a limited pool of phosphorylated NPM 
available for PP1β-mediated de-phosphorylation upon 
nucleolar stress, causing insufficient mobilization of NPM 
to the nucleoplasm thereby allowing HDM2 to maintain 
significant control over p53 (Figure 1). In line with these 
observations, NPM or TPL2 silencing impairs stress-
induced p53 stabilization in vitro and in vivo [2, 3, 6].
This work hints to an unprecedented duality in 
TPL2 function that depends on subcellular topology: 
transduction of pro-inflammatory signals in the cytoplasm 
and inhibition of tumorigenic pathways in the nucleus. 
However, a number of outstanding questions remain 
unanswered. How do these distinct TPL2 functions 
intertwine to achieve control of processes relevant to 
tumorigenesis such as cell cycle arrest, apoptosis and 
senescence? What is the relationship between nucleolar 
TPL2 and oncogene-induced ARF or the RPL5/RPL11/5S 
rRNA/HDM2/p53 signaling pathway? Do these pathways 
sense distinct stress-induced nucleolar lesions and do they 
synergize in p53 activation and tumor suppression?
An abundance of evidence has shown that 
inherited abnormalities in ribosome function can lead to 
tumorigenesis. Diamond Blackfan Anemia (DBA) is a 
rare inherited bone marrow failure syndrome caused by 
alterations in several RP genes and it typifies a group 
of disorders called ribosomopathies that are linked to 
mutations in genes encoding RPs or other factors involved 
in ribosome biogenesis [8]. DBA itself predisposes to 
myelodysplastic syndromes (MDS) which may further 
progress to AML. As errors in ribosome biosynthesis 
activate the RPL5/RPL11/5S rRNA/HDM2/p53 signaling 
pathway, it has been suggested that the selection of 
cells that loose expression of wild-type p53 or acquire 
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mutations in p53 or other signaling components of the 
RPL5/RPL11/5S rRNA/HDM2 complex may allow escape 
from the ribosome biogenesis stress-imposed checkpoint, 
thereby facilitating tumor progression. As AML cells 
show approximately 2-fold reduction in TPL2 mRNA 
levels [4], mutational inactivation of p53 and cytoplasmic 
localization of NPM [2], it can be postulated that the 
TPL2/NPM/HDM2/p53 response might also, alone or 
in synergy with the RPL5/RPL11/5S rRNA/HDM2/p53 
signaling pathway, inhibit progression of pre-neoplastic 
MDS cells to AML, a possibility that warrants further 
investigations.
The identification of TPL2 as a novel component 
of the nucleolar stress response may therefore contribute 
to better understanding of the pathogenesis of human 
diseases and the pursuit of TPL2 signaling will no doubt 
continue to provide invaluable insight into the complex 
biological functions of the nucleolus.
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Figure 1: Schematic representation of a novel TPL2/NPM/HDM2/p53 pathway activated upon nucleolar stress [3]. 
TPL2 physiologically functions to phosphorylate a pool of NPM (pNPM) targeting it for ubiquitination and degradation. Following 
nucleolar stress by UVC, pNPM becomes de-phosphorylated by activated PP1β, stabilizes and translocates to the nucleoplasm where it 
associates with HDM2 alleviating its effect on p53 degradation (left). The down-regulation of TPL2 expression observed in certain tumor 
types (right) affects the entire chain of nucleolar and nucleoplasmic events resulting in impaired p53 accumulation (see text for details).
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